Drug in Combination with Merck’s Blockbuster Keytruda Nearly Doubles Response Rate

Source: Michael Sheikh for Streetwise Reports   12/04/2017 Michael Sheikh, the founder of Falcon Strategic Research, delves into a biotech company whose trial results he believes could fuel takeover speculation. Rare Phase . . . → Read More: Drug in Combination with Merck’s Blockbuster Keytruda Nearly Doubles Response Rate Similar Articles: Analyst’s ‘Top Pick’ Advances Vaccine Candidates Biotech Targets ‘Blockbuster’ Markets; Less-Addictive Opioid Painkiller Set for FDA Filing Possible ‘Best-in-Class’ Alzheimer’s Drug Candidate Offers ‘Disruptive’ Potential